Cochrane · systematic review · CD008557
Intravenous immunoglobulins for epilepsy
Geng, J, Dong, J, Li, Y, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
2
No studies
2
Included studies
NR
No studies 2 · 50%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsIVIg compared to placebo for drug‐resistant epilepsy
Population: patients with drug‐resistant epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Seizure freedom IVIg vs placebo | no estimate extracted | NR | No studies |
Satisfactory seizure control 50% or greater reduction in seizure frequency for drug‐resistant epilepsy IVIg vs placebo | RR 1.89 [0.85, 4.21] | 1 study · 58 participants | Low Downgraded: risk of bias |
Incidence of adverse or harmful effects IVIg vs placebo | no estimate extracted | NR | No studies |
Global assessment IVIg vs placebo | RR 3.29 [1.13, 9.57] | 1 study · 60 participants | Low Downgraded: risk of bias |